Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
29 November 2022 | Story Andre Damons | Photo Andre Damons
Prof Motlalepula Matsabisa
Prof Motlalepula Matsabisa, Director of Pharmacology in the Department of Pharmacology at the UFS, hosted the first IKS Bio-Trade Indaba, which took place between 24 and 25 November on the Bloemfontein Campus of the UFS.

The inaugural international Indigenous Knowledge and Bio-Trade Indaba, hosted by the University of the Free State (UFS) in collaboration with the Technology Innovation Agency (TIA) – an entity of the Department of Science and Innovation (DSI) – is the ideal platform for various stakeholders to network and share knowledge on current developments in indigenous knowledge research and product development, biodiversity, conservation, innovation, and commercialisation of the IK-based researched products. 

The IKS Bio-Trade Indaba was championed by the university’s African Medicines Innovation and Technology Development Platform (AMITD), which is funded by TIA. AMITD was established to stimulate economic growth by providing science-based solutions and developing technologies that would utilise indigenous knowledge and South African biodiversity to produce high-quality African traditional-medicine-based proprietary products, focusing on priority diseases. AMITD is a national leader in research, development, and formulation research on traditional medicines and has a strong history in IKS research, community collaboration, and participation initiatives, as well as partnerships with industry on herbal medicines.

The indaba, which took place from 24 to 25 November, was a success, opening much-needed dialogue and engagement on the role of IK-based knowledge in research and commercialisation. Going forward, the indaba will be a vital platform to enhance the role of IKS in inclusive development and transformation.

African traditional medicine should be internationally recognised

Prof Motlalepula Matsabisa, Director of Pharmacology in the UFS Department of Pharmacology and AMITD, said he has a special interest in the pharmacology of traditional medicines and that he wants to see more national, continental, and international collaboration so that the dream of making ATM internationally recognised and a global force can be realised. 

“How do we develop new drugs and medicines based on the knowledge we have. We do this without compromising on good all-inclusive science on ATM. We should take the science and put it on the global stage so that all people will begin to respect it,” said Prof Matsabisa. 

According to him, research conducted by AMITD should address national research priorities, community research needs and aspirations to respond to industry research questions and challenges and develop products, intellectual property (IP), as well as commercialisation. “Research needs to have a societal impact and must impact the quality of life of people. We do responsive research that needs to address old diseases, new diseases, neglected diseases, current pandemics, as well as new and re-emerging pandemics.” 

Elevation of IKS profile can no longer be delayed
 
Dr Vuyisile Phehane, Executive: Bio-Economy at the TIA, said the indaba came at a time when the elevation of the profile of IKS can no longer be delayed. TIA acknowledges the rich, largely untapped source of knowledge within communities that has yet to be fully exploited for the economic and social benefit of particularly the underserved regions of the country, and it should be systematically well researched. 

Dr Vuysile Phehane
Dr Phehane, gave a message of support from TIA, saying the indaba came at a time when the elevation of the profile of IKS can no longer be delayed. (Photo: Andre Damons)


“Sectoral support priorities in agriculture, manufacturing, health innovations, and allied health cannot be overlooked, and neither can the various master plans created to support industrial sectors. This thought leadership has a direct bearing on what we are doing here, engaging in dialogue to shape our future, and seeking ways to collaborate and build long-lasting partnerships in the space of IKS. These partnerships not only serve us in the country, but also on the African continent,” said Dr Phehane. 

According to him, TIA played the role of industry builder and sought to increase its efforts to grow and enhance the role of IKS in inclusive development and transformation. The successful commercialisation of all indigenous knowledge-based projects involving the use of indigenous plants requires the capacity to commercially cultivate these plants. 

Dr Phehane said TIA funded AMITD to ensure that the products of promising indigenous knowledge innovations are safe, effective, and of consistently high quality. “This platform seeks to address generations of market failure by bringing IK into the mainstream of commercialisation and truly equitable benefit sharing. Going forward, 20% of our annual MTEF allocation will be channelled towards IK initiatives, which is significant. This is testament to our commitment to IKS.”

The two-day indaba hosted various panel discussions on multiple aspects of IKS research and developments in human and plant health. Among these were discussions on cannabis research to mitigate cancer multidrug resistance, phytoconstituents for the treatment of diabetes, the development of PHELA, a plant-based product as a treatment for COVID-19, natural product-based colon regulator commercialisation, the development of cannabis and other medicinal plants in wound healing and developing hydrogels, as well as the development of IK-based herbal pesticides.

Discussions also focused on new developments in the indigenous health infusion industry, developments in medicine regulations and IK-based clinical trials in South Africa, as well as African medicines research internationalisation. International panellists included Prof Minke Tang (Beijing University of Chinese Medicine), Dr Samuel Obakiro (HOD, Department of Pharmacology, Busitema University, Uganda), and Dr Kofi Donkor (Centre for Plant Medicine Research, Mampong, Ghana), all of whom shared experiences on IKS-related research in their respective countries.

IKS one of the areas targeted for investment and growth 

Dr Glen Taylor, Senior Director: Research Development at the UFS, said the Department of Pharmacology is one of the fastest-growing departments in the Faculty of Health Sciences at the UFS, and attracts a large number of applications from national and international scholars largely due to a very understated Prof Matsabisa.

“We always look at areas where we need to invest in the future and grow, and IKS is one of those areas we targeted and invested in significantly. Through the research and work in IKS, this is done to reposition the institution as a research-led university that is relevant to its communities and societies.” 
The TIA UFS IKS International Indaba was funded by the TIA IKS unit and the Department of Pharmacology – AMITD platform.

News Archive

Is milk really so well-known, asks UFS’s Prof. Osthoff
2011-03-17

Prof. Garry Osthoff
Photo: Stephen Collett

Prof. Garry Osthoff opened a whole new world of milk to the audience in his inaugural lecture, Milk: the well-known (?) food, in our Department of Microbial, Biochemical and Food Biotechnology of the Faculty of Natural and Agricultural Sciences.

Prof. Osthoff has done his research in protein chemistry, immuno-chemistry and enzymology at the Council for Scientific and Industrial Research (CSIR) in Pretoria and post-doctoral research at the Bowman-Grey School of Medicine, North Carolina, USA. That was instrumental in establishing food chemistry at the university.
 
He is involved in chemical aspects of food, with a focus on dairy science and technology. He is also involved in the research of cheese processing as well as milk evolution and concentrated on milk evolution in his lecture. Knowledge of milk from dairy animals alone does not provide all the explanations of milk as food.
 
Some aspects he highlighted in his lecture were that milk is the first food to be utilised by young mammals and that it is custom-designed for each species. “However, mankind is an opportunist and has found ways of easy access to food by the practice of agriculture, where plants as well as animals were employed or rather exploited,” he said.
 
The cow is the best-known milk producer, but environmental conditions forced man to select other animals. In spite of breeding selection, cattle seem not to have adapted to the most extreme conditions such as high altitudes with sub-freezing temperatures, deserts and marshes.
 
Prof. Osthoff said the consumption of the milk as an adult is not natural; neither is the consumption of milk across species. This practice of mankind may often have consequences, when signs of malnutrition or diseases are noticed. Two common problems are an allergy to milk and lactose intolerance.
 
Allergies are normally the result of an immune response of the consumer to the foreign proteins found in the milk. In some cases it might help to switch from one milk source to another, such as switching from cow’s milk to goat’s milk.
 
Prof. Osthoff said lactose intolerance – the inability of adult humans to digest lactose, the milk sugar – is natural, as adults lose that ability to digest lactose. The symptoms of the condition are stomach cramps and diarrhoea. This problem is mainly found in the warmer climates of the world. This could be an indication of early passive development of dairy technology. In these regions milk could not be stored in its fresh form, but in a fermented form, in which case the lactose was pre-digested by micro-organisms, and the human population never adapted to digesting lactose in adulthood.
 
According to Prof. Osthoff, it is basically the lactose in milk that has spurred dairy technology. Its fermentation has resulted in the development of yoghurts and all the cheeses that we know. In turn, the intolerance to lactose has spurred a further technological solution: lactose-free milk is currently produced by pre-digestion of lactose with enzymes.
 
It was realised that the milks and products from different species differed in quality aspects such as keeping properties and taste. It was also realised that the nutritional properties differed as well as their effects on health. One example is the mentioned allergy against cow’s milk proteins, which may be solved by the consumption of goat’s milk. The nutritional benefits and technological processing of milk aroused an interest in more information, and it was realised that the information gained from human milk and that of the few domesticated species do not provide a complete explanation of the properties of milk as food. Of the 250 species of milk which have been studied, only the milk of humans and a few domesticated dairy animals has been studied in detail.

Media Release
15 March 2011
Issued by: Lacea Loader
Director: Strategic Communication
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: news@ufs.ac.za

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept